# Amino acid profiling of COVID-19 patients blood serum

# Russkikh Ya.V. <sup>©</sup>,<sup>1</sup> Sushentseva N.N. <sup>©</sup>,<sup>1\*</sup> Popov O.S. <sup>©</sup>,<sup>2</sup> Apalko S.V. <sup>©</sup>,<sup>2</sup> Shimansky V.S. <sup>©</sup>,<sup>2</sup> Asinovskaya A.Yu.<sup>©</sup>,<sup>2</sup> Mosenko S.V. <sup>©</sup>,<sup>2</sup> Sarana A.M.<sup>©</sup><sup>2</sup> Scherbak S.G.<sup>©</sup>,<sup>2</sup>

<sup>1</sup>Saint Petersburg State Health Care Establishment the City Hospital No. 40 of Health Department of the Saint Petersburg Kurortniy District Administration, 197706, Sestroretsk, Russian Federation <sup>2</sup>Saint-Petersburg State University, Government of the Russian Federation, 199034, Saint-Petersburg, Russian Federation \*Correspondence: natalia@sushentseva.ru

# ABSTRACT

- 1 Main objectives of this study were to analyse metabolomic profile features of patients with COVID-19 using mass spectrometry
- 2 techniques while taking into account the clinical and laboratory history, and to study the relationship between the severity of COVID-
- 3 19 symptoms and the concentration of primary metabolites, primarily amino acids. We used frozen blood serum samples of 935
- 4 COVID-19 patients from the City Hospital No. 40 biobank collection. Metabolomic profile was studied by HPLS-MS/MS method. R
- 5 programming language was used for statistical data processing. The difference of metabolic profile of patients with COVID-19 de-
- 6 pending on the severity of the disease was revealed based on the performed analysis for 52 out of 84 detected compounds there
- 7 were differences with reliability p<0,01. Statistically significant differences in concentration were recorded for organic acids, amino
- 8 acids and their derivatives. Using samples from the biobank collection, a metabolomic study of the biomaterial of patients hospi-
- 9 talised with the diagnosis of COVID-19 was carried out. According to the results obtained, kynurenine, phenylalanine and acetylcar-
- 10 nitine were associated with the severity of COVID-19 infection.

## 11 INTRODUCTION

- 12 Recently, there has been an increasing number of studies devoted to the analysis of the blood metabolome for diagnosis and as-
- 13 sessment of disease severity 1-4. Metabolomic profiling of human biological fluids is of great interest in terms of opportunities to ob-
- 14 tain additional knowledge about the pathogenesis of diseases and possible therapeutic targets. Identification of factors that allow
- 15 predicting the risk of severe disease and its complications is an important task.
- 16 The main method of metabolome research is mass spectrometry (MS), which can determin a wide variety of compounds, including
- 17 disease markers, even at very low concentrations with high reliability, specificity and sensitivity. Amino acid spectrum reflects many
- 18 processes occurring in the body and may contain information about the course of many diseases. Plasma amino acids link all or-
- 19 gan systems and play an important physiological role as basic metabolites and regulators of metabolism. Accordingly, metabolic
- 20 changes occurring in diseases of various systems and organs will affect amino acid profiles, and the amino acid spectrum may serve
- as a prognostic factor or indicate the development of some diseases  $^{5}$ .
- 22 To date, many papers about metabolomic profile of patients with COVID-19 have been published. Most of them are aimed at deter-
- mining the unique metabolic signature of COVID-19 or at predicting the severity of the disease and/or mortality from it 1-3,6. It has
- 24 been noted that in many diseases, changes in the levels of certain amino acids can serve as a prognostic factor <sup>4,7</sup>.
- 25 Serum amino acid concentrations are quite strongly associated with COVID-19 symptomatology<sup>1,6-10</sup>. Nevertheless, the available
- 26 data about the involvement of individual amino acids in pathological processes vary considerably. Nevertheless, involvement of
- amino acid in pathological processes vary considerably according to available data. Thus, several studies reported that the level of
- 28 phenylalanine concentration was positively associated with symptom severity <sup>7,11,12</sup>, whereas other studies reported an inverse rela-
- 29 tionship  $^{13}$  or no such relationship  $^{9,14}$ .
- 30 The purpose of this work was to identify the features of the metabolomic (primarily amino acid) profile of patients infected with
- 31 COVID-19 with different severity and outcomes of the disease.

## 32 **RESULTS**

- 33 Concentration data for 84 compounds with non-zero values in at least a few repetitions of measurements were used for analysis.
- 34 The results of the primary metabolites analysis revealed differences in metabolomic profile according to disease severity for 52 out

- of 84 detected compounds (with significance p<0.01). The following metabolites showed the greatest difference when compar-
- ing groups by COVID-19 course severity: kynurenine (p<0.0001; lfc=1.62), phenylalanine (p<0.0001; lfc=1.13) and acetylcarnitine</li>
   (p<0.0001; lfc=1.28).</li>
- 38 Differences between groups with a high level of statistical significance were also found for the concentration of the following com-
- 39 pounds: citrulline, ornithine, cystine, dimethylglycine, asymmetric dimethylarginine (ADMA), alanine, cystathionine, carnosine, γ-
- 40 glutamylcysteine, arginine (Table ).
- 41 In addition, tyrosine, histidine, proline, threonine, symmetric dimethylarginine (SDMA), creatinine, adenosine, thymidine monophos-
- 42 phate (TMP), cytosine, S-Adenosyl-L-homocysteine (SAH), and nicotinamide levels changed consistently with the progression of
- 43 COVID-19 infection severity.
- 44 Differences in the metabolic profile between patients from group I and group II were observed for more than 30 compounds (Ta-
- 45 ble ). Elevated levels of kynurenine, phenylalanine, acetylcarnitine, dimethylglycine, proline, cytosine, tyrosine, adenosine, SAH, TMP,
- 46 and to a lesser extent isoleucine, allantoin, asparagine, aspartate, 4-hydroxyproline, cystathionine were detected for group II pa-
- 47 tients, lysine, glycine,  $\gamma$ -glutamylcysteine, glutathione, valine, serine, adenosine monophosphate (AMP),  $\alpha$ -ketoglutarate, malate, oro-
- 48 tate, creatine, citrate, α-aminobutyrate, niacin, hypoxanthine, homocystine, choline, uridine, creatinine, carnitine, nicotinamide, oph-
- 49 thalmic acid, carnosine, guanosine, adenine, adrenaline, histamine. At the same time, the levels of threonine, ornithine, citrulline,
- 50 cysteine, ADMA, SDMA, histidine, arginine, alanine, isocitrate, pyruvate, AMP, glycine, norepinephrine, S-adenosyl methionine (SAM),
- 51 and cholate were lower in group II than in group I.
- 52 The metabolic profile of group III patients was characterized by further changes in the levels of the same compounds that distin-
- 53 guished group I from group II. Additionally, differences in the levels of isocitrate, AMP and uracil were noted.
- 54 Meanwhile, the metabolomic profiles of groups I and III differed in levels of 4-hydroxyproline, allantoin, SDMA, uridine, adenosine 55 and SAH.
- 56 Differences in metabolomic profiles between surviving and deceased patients were observed for 37 compounds out of 82 (Table ).
- 57 Differences with a high level of significance were recorded for cystine (p<0.0005; lfc=1.36), cysteine (p<0.0001; lfc=1.81) and dimethyl-
- 58 glycine (p<0.0001; lfc=1.29). Significantly lower levels of threonine, cysteine, homocystine, hydroxylysine, hypoxanthine, isocitrate,
- 59 pyruvate, cholate, and serotonin were observed in the metabolome of deceased patients. At the same time, the levels of kynure-
- nine, phenylalanine, citrulline, cytosine, dimethylglycine, histamine, γ-glutamylcysteine, cystine, carnitine, creatinine, creatine, cys-
- 61 tathionine, leucine, isoleucine, AMP, TMF, SAH, acetylcarnitine, α-ketoglutarate, malate, lactate, urate, fumarate, nicotinamide, pan-
- 62 tothenic acid and dopamine were higher than in surviving patients.

# 63 DISCUSSION

- 64 According to the results obtained, kynurenine, phenylalanine and acetylcarnitine have strong association with the severity of COVID-
- 19 infection. This is consistent with the findings of increased levels of kynurenine and phenylalanine for COVID-19 patients <sup>3,8,15,16</sup>
- and their negative correlation with the severity of infection <sup>7,10</sup>. Increased kynurenine levels in COVID-19 are associated with in-
- 67 creased tryptophan degradation due to overactivation of the immune response through increased levels of interferon-gamma (in-
- creased inflammatory response) and strong T-cell activation <sup>1,15</sup>; kynurenine pathway metabolites were shown to be associated
- 69 with tricarboxylic acid cycle intermediates, inflammatory response, and cell death<sup>4</sup>.
- 70 Acetylcarnitine plays an essential role in energy metabolism and transport of fatty acids into mitochondria. An imbalance of acetyl-
- carnitine in COVID-19 infection has been reported in a number of studies  $^{3,11,15}$ .
- 72 A strong correlation with COVID-19 infection severity was also recorded for citrulline, ornithine, cystine, dimethylglycine, ADMA, ala-
- 73 nine, cystathionine, carnosine, γ-glutamylcysteine, and arginine.
- 74 In addition, levels of tyrosine, adenosine, histidine, creatinine, TMP, proline, threonine, cytosine, SDMA, SAH, nicotinamide were con-
- 75 sistently altered as the severity of COVID-19 infection progressed, which is consistent with the data on the correlation of tyrosine
- 76 biosynthesis pathways with the severity of COVID-19 infection 17[17], as well as the relationship between the severe course of COVID-

- 19 and levels of such amino acids as phenylalanine, proline, valine, valine, glutamate, glutamine, tryptophan, histidine, alanine, leucine,
  isoleucine, cysteine<sup>18,19</sup>.
- 79 Impaired synthesis and metabolism of arginine, threonine, ornithine, citrulline and alanine in COVID-19 patients, especially un-
- 80 der hypoxic conditions, has been reported in many studies <sup>9,11,16,19</sup>. Decreased serum levels of glutamate, citrulline, ornithine, glu-
- tamine, urea, fumarate, ADMA and SDMA in COVID-19 patients were associated with liver dysfunction <sup>14</sup>.
- 82 Metabolic profile of patients with COVID-19 in severe condition (group III) was characterized by significantly greater changes com-
- pared with groups I and II (Table 3) and affected all classes of metabolites studied, indicating systemic metabolic disorders resulting
   from the development of COVID-19 and affecting the functioning of various organs and systems of the body.
- 85 Citrullin is produced almost exclusively by enterocytes and is used as a biomarker of small intestinal enterocyte mass and function.
- 86 COVID-19 can infect human intestinal cells and also replicate in intestinal epithelial cell lines and organoid models of human colon,
- 87 thus participating in the spread of COVID-19 with increased viremia<sup>20</sup>. A study of differences in plasma amino acid levels between
- 88 the acute and convalescent stages in people with community-acquired pneumonia showed that plasma levels of arginine and cit-
- 89 rulline decreased <sup>19</sup>, which is consistent with our findings.
- 90 Elevated plasma cytosine levels in COVID-19 patients may be associated with virus escape from innate immunity<sup>21</sup>, and cytosine-
- 91 based metabolites are coordinators of cellular metabolism in COVID-19, and are important for innate antiviral immunity and virus
- 92 evolution. Observed significant increase of creatine and creatinine in metabolomic profiles of deceased patients compared to sur-
- 93 vivors indicates the development of renal dysfunction 15.
- 94 The most significant differences in metabolic profiles between surviving and deceased patients were recorded for cystine, cysteine
- and dimethylglycine. Reduction of dimethylglycine level in patients with unfavorable course of COVID-19 was also noted by Silvagno F, et al.<sup>22</sup>.
- 97 Decreased glutathione levels were observed <sup>22,23</sup> in diseases that increase the risk of COVID-19, and the resulting glutathione de-
- 98 ficiency was associated with the severity of course and death in patients with COVID-19. An increase in cystine and cysteine levels
- in the plasma of COVID-19 patients with increasing severity of infection (from moderate to severe) was also reported in Bramer et
- 100 al.<sup>24</sup>. Cystine is formed in the extracellular space from reduced glutathione, functions as a general marker of infection and can serve
- as an indicator of glutathione production and activity of its cycle under oxidative stress<sup>22,24</sup>.
- 102 Imbalance of cystine and cysteine depending on COVID-19 disease severity, immune activity and presence of comorbidities was
- also reported by Páez-Franco JC<sup>25</sup>[25]. It has been observed that cystine levels are crucial for the control of reactive oxygen species
- in COVID-19 as well as in some malignancies. Alanine transaminase, aspartate transaminase and cystine levels correlation in severe
- 105 COVID-19 patients may indicate a potential involvement of the liver in cysteine and cystine metabolism in COVID-19, which may
- be likely since this organ is the main site of glutathione synthesis and often is affected in severe cases of COVID-19<sup>25</sup>.
- 107 Cysteine/cystine, cysteinylglycine/cystinylglycine and glutathione/glutathione disulfide are the main redox pairs for maintaining of
- 108 extracellular thiol-disulfide balance. They are indicators of an age-related decrease in systemic reduction potential and the influence
- 109 of this process on various tissues, including the pulmonary<sup>26</sup>. COVID-19 disrupts cellular the cystine/cysteinic cycle and extracel-
- 110 lular thyols redox homeostasis mechanisms. It promotes the replication of the virus due to the formation of pro-oxidants in the in-
- 111 fected tissue. Indeed, the preferential incorporation of cellular cysteine into viral proteins rather than into glutathione of cellular pro-
- teins has been observed as a common mechanism in other types of viral infections  $^{26}$ .
- 113 Increased SAM levels in the metabolomic profiles of patients with high comorbidity index values can be considered as a marker of
- 114 lung damage risk in COVID-19 patients and possibly as a factor associated with the development of inflammation, since SAM and
- 115 SAH are indicators of transmethylation and may play an important role as markers of COVID-19 severity<sup>27</sup>.

#### 116 MATERIALS AND METHODS

#### 117 Participant Characteristics

- 118 A frozen blood serum from the City Hospital No 40 biobank collection was used to amino acids profiling. The study was approved
- by the expert ethics board of the St. Petersburg State Health Care Institution "City Hospital No. 40" (protocol No. 171 dated May 18,

- 120 2020). All donors had signed voluntary informed consent to participate in the study.
- 121 Serum samples from 935 patients (445 males and 490 females) were included in the study (Table 1)
- 122 Participation criteria:
- 123 1. Positive PCR test for COVID-19
- 124 2. Voluntary informed consent to participate in the study.
- 125 3. No history of HIV, hepatitis B and C, or syphilis. 4.
- 126 4. Blood collection was performed before anticytokine therapy, hemosorption, transfusion of blood and its components.
- 127 Patients were divided into groups according to the severity of the disease. Severity level was determined by the current version of
- 128 the "Interim Guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)": (I) "mild" group of pa-
- 129 tients with mild COVID-19 infection without changes on a computed tomography (CT) scan characteristic of a viral lesion (16 males
- and 9 females); (II) "moderate" group of patients with elevated body temperature (>38 degrees C), relatively low blood oxygen
- 131 saturation and changes on a CT scan typical of a viral lesion (263 men and 301 women), (III) "severe" group of patients with a se-
- vere course of COVID-19 infection, with decreased level of consciousness, unstable hemodynamics and changes on CT scan up to
- critical degree of lesion and development of acute respiratory distress syndrome (166 men and 180 women). Group IV patients
- 134 with fatal outcome of the disease (total 73 men and 68 women), and surviving patients group V were used as a comparison group.

#### 135 Metabolite profile study method

- 136 2-(N-morpholino)ethanesulfonic acid and L-methionine sulfone (Sigma-Aldrich) were used as internal standards. The samples were
- thawed at room temperature, then 100 tl of a solution of the internal standard mixture in acetonitrile was added to 50 tl of serum.
- 138 The obtained extract was diluted with water. The prepared standard solutions and extracts were stored at -20 C.
- 139 The metabolite profile was analyzed using LCMS-8050 triple quadrupole liquid chromatography-mass spectrometer (Shimadzu)
- 140 with Nexera X2 chromatography system. HPLC-MS/MS Analysis was performed using the commercially available "LC/MS/MS Method
- 141 Package for Primary Metabolites" method for the analysis of primary metabolites using a Discovery HS F5-3 analytical column (150 ± 2.1
- 142 mm, 3 m) (Supelco, Merck) in multiple reaction monitoring mode. The method allows simultaneous analysis of 98 primary metabo-
- lites (Table 2) including amino acids, organic acids, nucleotides, nucleosides, and coenzymes. Mass spectrometric and chromato-
- 144 graphic conditions and parameters were set according to the method instruction "LC/MS/MS Method Package for Primary Metabo-
- 145 lites". Data was collected and processed using LabSolutions software according to the internal standard method.

#### 146 Statistical processing of data

- 147 The Shapiro-Wilk test was used to test the hypothesis of normal distribution of data. One-factor analysis of variance using the Kraskell-
- 148 Wallis test was used to detect intergroup differences in the concentration levels of the compounds under study, and the Mann-
- 149 Whitney test was used as a post-hoc analysis. The logarithm of fold change (lfc) was used as a measure of the difference in the range
- of values between samples, descriptive statistics was represented by the median (Me) and interquartile range [Q25-Q75]. Data pro-
- 151 cessing and statistical analysis were performed using the R programming language version 4.3.1.

#### ACKNOWLEDGMENTS

The authors are grateful to the study participants and the staff from the St. Petersburg State Health Care Institution City Hospital No. 40, Kurortny District hospital. The authors would like to thank all authors of the included studies for their valuable contributions to data collection, and Saint-Petersburg University R&D grant for making this study possible.

## AUTHOR COMPETING INTERESTS

The authors declare no conflict of interests.

## REFERENCES

- X. Chen, M. Gu, T. Li, and Y. Sun, "Metabolite reanalysis revealed potential biomarkers for covid-19: a potential link with immune response," *Future Microbiology*, vol. 16, pp. 577–588, 5 2021. [Online]. Available: /pmc/articles/PMC8112156//pmc/articles/ PMC8112156/?report=abstracthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112156/
- [2] M. Mierzchala-Pasierb, M. Lipinska-Gediga, M. G. Fleszar, P. Lesnik, S. Placzkowska, P. Serek, J. Wisniewski, A. Gamian, and M. Krzystek-Korpacka, "Altered profiles of serum amino acids in patients with sepsis and septic shock - preliminary findings," *Archives of biochemistry and biophysics*, vol. 691, 9 2020. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32712289/
- [3] M. Costanzo, M. Caterino, R. Fedele, A. Cevenini, M. Pontillo, L. Barra, and M. Ruoppolo, "Covidomics: The proteomic and metabolomic signatures of covid-19," *International Journal of Molecular Sciences*, vol. 23, p. 2414, 3 2022. [Online]. Available: /pmc/articles/PMC8910221//pmc/articles/PMC8910221/?report=abstracthttps://www.ncbi.nlm.nih.gov/ pmc/articles/PMC8910221/
- [4] N. V. Beloborodova, A. Y. Olenin, and A. K. Pautova, "Metabolomic findings in sepsis as a damage of hostmicrobial metabolism integration," *Journal of critical care*, vol. 43, pp. 246–255, 2 2018. [Online]. Available: https: //pubmed.ncbi.nlm.nih.gov/28942199/
- [5] A. Synakiewicz, A. Stanislawska-Sachadyn, M. Sawicka-Zukowska, G. Galezowska, J. Ratajczyk, A. Owczarzak, M. Skuza, L. Wolska, and T. Stachowicz-Stencel, "Plasma free amino acid profiling as metabolomic diagnostic and prognostic biomarker in paediatric cancer patients: a follow-up study," *Amino acids*, vol. 53, pp. 133–138, 1 2021. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/33179163/
- [6] A. M. Philips and N. Khan, "Amino acid sensing pathway: A major check point in the pathogenesis of obesity and covid-19," Obesity reviews : an official journal of the International Association for the Study of Obesity, vol. 22, 4 2021. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/33569904/
- [7] A. Atila, H. Alay, M. E. Yaman, T. C. Akman, E. Cadirci, B. Bayrak, S. Celik, N. E. Atila, A. M. Yaganoglu, Y. Kadioglu, Z. Halc, E. Parlak, and Z. Bayraktutan, "The serum amino acid profile in covid-19," *Amino acids*, vol. 53, pp. 1569–1588, 10 2021. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/34605988/
- [8] C. A. Rees, C. A. Rostad, G. Mantus, E. J. Anderson, A. Chahroudi, P. Jaggi, J. Wrammert, J. B. Ochoa, A. Ochoa, R. K. Basu, S. Heilman, F. Harris, S. A. Lapp, L. Hussaini, M. B. Vos, L. A. Brown, and C. R. Morris, "Altered amino acid profile in patients with sars-cov-2 infection," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 118, p. e2101708118, 6 2021. [Online]. Available: https://www.pnas.org/doi/abs/10.1073/pnas.2101708118
- [9] J. C. Páez-Franco, J. Torres-Ruiz, V. A. Sosa-Hernández, R. Cervantes-Díaz, S. Romero-Ramírez, A. Pérez-Fragoso, D. E. Meza-Sánchez, J. M. Germán-Acacio, J. L. Maravillas-Montero, N. R. Mejía-Domínguez, A. P. de León, A. Ulloa-Aguirre, D. Gómez-Martín, and L. Llorente, "Metabolomics analysis reveals a modified amino acid metabolism that correlates with altered oxygen homeostasis in covid-19 patients," *Scientific reports*, vol. 11, 12 2021. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/33737694/
- [10] J. W. Song, S. M. Lam, X. Fan, W. J. Cao, S. Y. Wang, H. Tian, G. H. Chua, C. Zhang, F. P. Meng, Z. Xu, J. L. Fu, L. Huang, P. Xia, T. Yang, S. Zhang, B. Li, T. J. Jiang, R. Wang, Z. Wang, M. Shi, J. Y. Zhang, F. S. Wang, and G. Shui, "Omics-driven systems interrogation of metabolic dysregulation in covid-19 pathogenesis," *Cell metabolism*, vol. 32, pp. 188–202.e5, 8 2020. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32610096/
- [11] E. Barberis, S. Timo, E. Amede, V. V. Vanella, C. Puricelli, G. Cappellano, D. Raineri, M. G. Cittone, E. Rizzi, A. R. Pedrinelli, V. Vassia, F. G. Casciaro, S. Priora, I. Nerici, A. Galbiati, E. Hayden, M. Falasca, R. Vaschetto, P. P. Sainaghi, U. Dianzani, R. Rolla, A. Chiocchetti, G. Baldanzi, E. Marengo, and M. Manfredi, "Large-scale plasma analysis revealed new mechanisms and molecules associated with the host response to sars-cov-2," *International journal of molecular sciences*, vol. 21, pp. 1–25, 11 2020. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/33207699/
- [12] F. X. Danlos, C. Grajeda-Iglesias, S. Durand, A. Sauvat, M. Roumier, D. Cantin, E. Colomba, J. Rohmer, F. Pommeret, G. Baciarello, C. Willekens, M. Vasse, F. Griscelli, J. E. Fahrner, A. G. Goubet, A. Dubuisson, L. Derosa, N. Nirmalathasan, D. Bredel, S. Mouraud, C. Pradon, A. Stoclin, F. Rozenberg, J. Duchemin, G. Jourdi, S. Ellouze, F. Levavasseur, L. Albigès, J. C. Soria, F. Barlesi, E. Solary, F. André, F. Pène, F. Ackerman, L. Mouthon, L. Zitvogel, A. Marabelle, J. M. Michot, M. Fontenay, and G. Kroemer, "Metabolomic analyses of covid-19 patients unravel stage-dependent and prognostic biomarkers," *Cell death disease*, vol. 12, 3 2021. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/33707411/
- [13] M. Caterino, M. Costanzo, R. Fedele, A. Cevenini, M. Gelzo, A. D. Minno, I. Andolfo, M. Capasso, R. Russo, A. Annunziata, C. Calabrese, G. Fiorentino, M. Dabbraccio, C. Dellisola, F. M. Fusco, R. Parrella, G. Fabbrocini, I. Gentile, G. Castaldo, and M. Ruoppolo, "The serum metabolome of moderate and severe covid-19 patients reflects possible liver alterations involving carbon and nitrogen metabolism," *International journal of molecular sciences*, vol. 22, 9 2021. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/34502454/
- [14] B. Shen, X. Yi, Y. Sun, X. Bi, J. Du, C. Zhang, S. Quan, F. Zhang, R. Sun, L. Qian, W. Ge, W. Liu, S. Liang, H. Chen, Y. Zhang, J. Li, J. Xu, Z. He, B. Chen, J. Wang, H. Yan, Y. Zheng, D. Wang, J. Zhu, Z. Kong, Z. Kang, X. Liang, X. Ding, G. Ruan, N. Xiang, X. Cai, H. Gao, L. Li, S. Li, Q. Xiao, T. Lu, Y. Zhu, H. Liu, H. Chen, and T. Guo, "Proteomic and metabolomic characterization of covid-19 patient sera," *Cell*, vol. 182, pp. 59–72.e15, 7 2020. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32492406/
- [15] T. Thomas, D. Stefanoni, J. A. Reisz, T. Nemkov, L. Bertolone, R. O. Francis, K. E. Hudson, J. C. Zimring, K. C. Hansen, E. A. Hod, S. L. Spitalnik, and A. DAlessandro, "Covid-19 infection alters kynurenine and fatty acid metabolism, correlating with il-6 levels and renal status," *JCI insight*, vol. 5, 6 2020. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32559180/
- [16] F. C. Ceballos, A. Virseda-Berdices, S. Resino, P. Ryan, O. Martínez-González, F. Peréz-García, M. Martin-Vicente, O. Brochado-Kith, R. Blancas, S. Bartolome-Sánchez, E. J. Vidal-Alcántara, O. E. Albóniga-Díez, J. Cuadros-González, N. Blanca-López, I. Martínez, I. R. Martinez-Acitores, C. Barbas, A. Fernández-Rodríguez, and M. Ángeles Jiménez-Sousa, "Metabolic profiling at covid-19 onset shows disease severity and sex-specific dysregulation," *Frontiers in immunology*, vol. 13, 6 2022. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/35844615/
- [17] A. Valdés, L. O. Moreno, S. R. Rello, A. Orduña, D. Bernardo, and A. Cifuentes, "Metabolomics study of covid-19 patients in four different clinical stages," *Scientific reports*, vol. 12, 12 2022. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/35102215/
- [18] I. Maltais-Payette, F. Lajeunesse-Trempe, P. Pibarot, L. Biertho, and A. Tchernof, "Association between circulating amino acids and covid-19 severity," *Metabolites*, vol. 13, 2 2023. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/36837819/
- [19] A. Ozturk, N. Bayraktar, M. Bayraktar, B. Ibrahim, T. Bozok, and M. R. Ceylan, "Evaluation of amino acid profile in serum of patients with covid-19 for providing a new treatment strategy," *Journal of medical biochemistry*, vol. 41, pp. 526–533, 2022. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/36381071/

- [20] M. L. Stanifer, C. Kee, M. Cortese, C. M. Zumaran, S. Triana, M. Mukenhirn, H. G. Kraeusslich, T. Alexandrov, R. Bartenschlager, and S. Boulant, "Critical role of type iii interferon in controlling sars-cov-2 infection in human intestinal epithelial cells," *Cell reports*, vol. 32, 7 2020. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32610043/
- [21] A. Danchin and P. Marlière, "Cytosine drives evolution of sars-cov-2," Environmental microbiology, vol. 22, pp. 1977–1985, 6 2020. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32291894/
- [22] J. Pera-Kaján and H. Jakubowski, "Covid-19 and one-carbon metabolism," *International journal of molecular sciences*, vol. 23, 4 2022. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/35456998/
- [23] F. Silvagno, A. Vernone, and G. P. Pescarmona, "The role of glutathione in protecting against the severe inflammatory response triggered by covid-19," *Antioxidants*, vol. 9, pp. 1–16, 7 2020. [Online]. Available: /pmc/articles/PMC7402141//pmc/articles/ PMC7402141/?report=abstracthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402141/
- [24] L. M. Bramer, R. D. Hontz, A. J. Eisfeld, A. C. Sims, Y. M. Kim, K. G. Stratton, C. D. Nicora, M. A. Gritsenko, A. A. Schepmoes, O. Akasaka, M. Koga, T. Tsutsumi, M. Nakamura, I. Nakachi, R. Baba, H. Tateno, S. Suzuki, H. Nakajima, H. Kato, K. Ishida, M. Ishii, Y. Uwamino, K. Mitamura, V. L. Paurus, E. S. Nakayasu, I. K. Attah, A. G. Letizia, K. M. Waters, T. O. Metz, K. Corson, Y. Kawaoka, V. R. Gerbasi, H. Yotsuyanagi, and K. Iwatsuki-Horimoto, "Multi-omics of net formation and correlations with cndp1, pspb, and l-cystine levels in severe and mild covid-19 infections," *Heliyon*, vol. 9, 3 2023. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/36915486/
- [25] J. C. Páez-Franco, J. L. Maravillas-Montero, N. R. Mejía-Domínguez, J. Torres-Ruiz, K. M. Tamez-Torres, A. Pérez-Fragoso, J. M. Germán-Acacio, A. Ponce-De-León, D. Gómez-Martín, and A. Ulloa-Aguirre, "Metabolomics analysis identifies glutamic acid and cystine imbalances in covid-19 patients without comorbid conditions. implications on redox homeostasis and covid-19 pathophysiology," *PloS one*, vol. 17, 9 2022. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/36126080/
- [26] F. Galli, G. Marcantonini, D. Giustarini, M. C. Albertini, A. Migni, L. Zatini, A. Gioiello, R. Rossi, and D. Bartolini, "How aging and oxidative stress influence the cytopathic and inflammatory effects of sars-cov-2 infection: The role of cellular glutathione and cysteine metabolism," *Antioxidants (Basel, Switzerland)*, vol. 11, 7 2022. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/35883857/
- [27] E. V. Kryukov, A. V. Ivanov, V. O. Karpov, V. V. Aleksandrin, A. M. Dygai, M. P. Kruglova, G. I. Kostiuchenko, S. P. Kazakov, and A. A. Kubatiev, "Plasma s-adenosylmethionine is associated with lung injury in covid-19," *Disease Markers*, vol. 2021, 2021. [Online]. Available: /pmc/articles/PMC8702356//pmc/articles/PMC8702356//pmc/articles/PMC8702356/

**Table 1:** Sex and age structure of the examined groups of patients  $[M \pm SD]$ 

Comparison	Group	n	n (M)	n (F)	Age	Age (M)	Age(F)
Disease		25	16	9	$51 \pm 16, 2$	$50,9 \pm 16,6$	$51, 3 \pm 16, 3$
course	П	564	263	301	$61, 5 \pm 15, 5$	$59,7\pm15,3$	$63, 1 \pm 15, 5$
severity (n=935)	111	346	166	180	$69, 1 \pm 14, 2$	$67, 1 \pm 14, 3$	$70,9 \pm 13,8$
Disease outcome	IV	141	73	68	$74, 8 \pm 12, 4$	$73 \pm 12, 1$	$76, 7 \pm 12, 5$
(n=935)	V	794	372	422	$62, 1 \pm 15, 3$	$60 \pm 15, 2$	$64 \pm 15, 2$

Note: I - group of patients with mild course of the disease, II - group of patients with moderately severe course of the disease, III - group of patients with severe course of the disease, IV - group of patients with fatal outcome of the disease, V - group of patients successfully discharged after hospitalisation. Comparison - parameter by which the studied groups are compared, in brackets [n] is given the total number of patients from the sample included in the groups. M - male, F - female.

### Table 2: List of primary metabolites

Glycolysis	Organic acids
Lactic acid	γ-Aminobutyric acid
Pyruvic acid	Adenylosuccinate
Citric acid cycle	Argininosuccinic acid
α-Ketoglutaric acid	Cholic acid
Aconitic acid	Creatine
Citric acid	Niacin
Fumaric acid	Ophthalmic acid
Isocitric acid	Orotic acid
Malic acid	Pantothenic acid
Succinic acid	Taurocholic acid
Amino acids	Uric acid
4-Hydroxyproline	Nucleosides and nucleotides
Alanine	Adenine
Arginine	Cvtosine
Asparagine	Guanine
Aspartic acid	Thymine
l vsine	Uracil
itrulline	Xanthine
Cystine	Adenosine
Dimethylalycine	Cvtidine
Glutamic acid	Guanosine
Glutamine	Inosine
Glycine	Thymidine
Histidine	Uridine
Homocystine	3' 5'-cyclic adenosine monophosphate
Isoleucine	AMP
Leucine	3' 5'-cyclic cytidine monophosphate
Asymmetric dimethylarginine (ADMA)	Cvtidine monophosphate
Methionine sulfoxide	3' 5'-cyclic guanosine monophosphate
Symmetric dimethylarginine (SDMA)	Guanosine monophosphate
Phenylalanine	Thymidine
Proline	Other compounds
Serine	α-Aminobutyric acid
Ornithine	Acetylcarnitine
Threonine	Acetylcholine
Tryptophan	Allantoin
Tyrosine	Carnitine
Valine	Carnosine
, anno	Choline
Transsulfuration pathway	Citicoline
Cystathionine	Creatinine
Cysteine	Cysteamine
Homocysteine	3 4-dihydroxyphenylalanine
Methionine	Dopamine
r-glutamylcysteine	Adrenaline
Glutathione	Histamine
Oxidized alutathione	Hypoxanthine
S-adenosyl-L-homocysteine (SAH)	Kynurenine
S-adenosyl methionine (SAM)	Nicotinamide
	Norepinephrine
Cofactors	Serotonin
FAD (Flavin adenine dinucleotide)	Internal standards
EMN (Flavin mononucleotide)	2-(N-morpholino)ethanesulfonic acid
NAD (Nicotinamide adenine dinucleotide)	I -Methionine sulfone

Table 3: Metabolite concentrations in the blood of patients from different groups divided by disease severity [Me (Q25-Q75)], numbers less than 0.001 are presented by exponential entry [number e degree]

Metabolite	I (Mild)	II (Moderate)	III (Severe)	Significance	I, II	1, 111	11, 111
	0,191	1,77	2,76	, in the second			
Cystine	(0.170.0.557)	(0.007.5.(.))	(0.705.5.05)	<0,001	0,001	<0,001	0,001
	(0,132-0,667)	(0,207-5,44)	(0,395-6,07)				
Asparagine	1,03	2,0	2,0	<0.001	<0.001	<0.001	0249
, opulagine	(0,778-1,95)	(1,74-3,94)	(1,76-4,11)	0,001	0,001	0,001	0,215
	1,45	2,32	2,17				
Aspartic acid	(0.500.1.70)	(2 5 2 7 7 2)	(1.57.7.70)	<0,001	<0,001	<0,001	0,445
	(0,692-1,78)	(1,51-3,31)	(1,53-3,38)				
Alanine	54,4	21,4	16,5	<0.001	<0.001	<0.001	<0.001
Additine	(25.3-38.7)	(12-32.6)	(10.4-27.5)	-0,001	-0,001	-0,001	-0,001
	( ), , , , , , , , , , , , , , , , , , ,		0,201				
Cystathionine	0,042 (0,015-0,08)	0,147 (0,085-0,298)		<0,001	<0,001	<0,001	<0,001
			(0,11-0,439)				
Malic acid	0,009 (0,002-0,016)	0,0157 (0,0065-0,0247)	0,022 (0,013-0,038)	<0,001	0,029	<0,001	<0,001
Cysteine	4 12	2.76	2 02	<0,001	0,111	0,001	<0,001
itrulline	7,12	2,70	2,02	<0.001	0.001	<0.001	<0.001
	(3,18-5,76)	(0,88-4,54)	(0,85-3,35)	-,	-,	-,	-,
	10,1	26,9	31,8				
Proline	(0 (1 1 5 0)	(110.440)	(1 ( 5 5 1 0)	<0,001	<0,001	<0,001	0,033
	(8,41-16,9)	(11,9-44,9)	(14,6-51,8)				
Ornithine	7,87	5,65	4,47	<0.001	0.005	<0.001	<0.001
Official	(6.29-10.6)	(3.12-9.3)	(2.79-6.85)	-0,001	0,005	-0,001	-0,001
	0,001	0,004					
TMP			0,029 (0,001-0,358)	<0,001	0,002	<0,001	<0,001
	(0-0,002)	(0-0,074)					
Sarina	9,43	15 (0 7 21 /)	15	<0.001	<0.001	-0.001	0.702
Senne	(2 76-11 6)	15 (9,7-21,4)	(9.04-19.9)	<0,001	<0,001	<0,001	0,392
	(2,70 22,0)		0				
Fumaric acid	O (O-O)	O (O-O)	-	<0,001	0,005	<0,001	<0,001
	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	(0-0,007)				
			0,009				
γ-glutamylcysteine	0 (0-0)	0 (0-0,014)	(0.0.03.0)	<0,001	<0,001	<0,001	<0,001
	26.0	707	(0-0,018)				
Creatinine	26,9	38,7	44,8	<0.001	<0.001	<0.001	0.001
Credumine	(23.9-32.3)	(29.5-53.1)	(30.8-60.5)	-0,001	-0,001	-0,001	0,001
Norepinephrine	2,99 (1,58-3,39)	1,54 (0,106-2,48)	1,19 (0,086-2,33)	<0,001	<0,001	<0.001	0,022
Carnosine	0,07 (0,03-0,11)	0,0257 (0,006-0,07)	0,017 (0,004-0,055)	<0,001	0,003	<0,001	0,001
SAM	1,3e-10 (0-0,004)	0 (0-0,003)	0 (0-0)	<0,001	0,022	<0,001	0,001
ADMA	0,504 (0,419-0,659)	0,233 (0,007-0,52)	0,041 (0,004-0,4)	<0,001	<0,001	<0,001	0,001
SDMA	0,132 (1,28e-10-0,588)	0,034 (0,008-0,134)	0,018 (0-0,098)	<0,001	0,085	0,004	<0,001
SAH	1,21/0,917 1.99)	1.6 (117.2.19)	1.96 (1.29.2.96)	<0,001	0,568	0,008	<0,001
kynulenine	1,21 (0,813-1,98)	1,0 (1,13-2,19)	1,90 (1,29-2,00)	<0,001	0,012	<0,001	<0,001
Phenylalanine	10,		1,0	<0.001	0.021	< 0.001	< 0.001
	(59,2-148)	(82,8-219)	(106-243)				
	45,5	68,2	86				
Acetylcarnitine		(	(	<0,001	0,002	<0,001	<0,001
	(36,4-57,9)	(43-103)	(52,6-135)				
Histomine	0 (0-0 01 1)	0,0154	0.022 (0.006-0.048)	<0.001	<0.001	<0.001	<0.001
- instarrinic	0 (0 0,011)	(0-0.029)	0,022 (0,000 0,040)	-0,001	-0,001	-0,001	-0,001
Allantoin	0,01 (0,006-0,0147)	0,015 (0,007-0,023)	0,017 (0,01-0,032)	0,001	0,047	0,002	<0,001
Dimethylglycine	1,32 (0,898-1,83)	1,83 (1,25-2,66)	2,1 (1,3-3,64)	0,001	0,005	<0,001	0,002
Glycine	2,4 (0,838-4,04)	3,78 (2,5-5,65)	3,3 (2,19-4,86)	0,001	0,005	0,046	<0,001
Carnitine	20,4 (17,5-24,2)	26,4 (20,8-33,4)	27,5 (21,2-34,8)	0,001	<0,001	<0,001	0,182
Threonine	7 48 (5.87-10.4)	805 (592-112)	7.07 (4.81-10.1)	0,0012	<0,001	<0,001	<0.001
Pyruvic acid	0 (0-0.043)	0.027 (0-0.052)	0.021 (0-0.036)	0,0012	0,245	0,803	<0,001
Citric acid	0 (0-0.064)	0.067 (0.02-0.153)	0.069 (0.016-0.191)	0.001	< 0.001	< 0.001	0.46
Adenosine	0,132 (0,063-0,186)	0,166 (0,065-0,435)	0,245 (0,087-0,46)	0,001	0,112	0,005	0,001
Serotonin	0,046 (0,029-0,096)	0,08 (0,032-0,19)	0,047 (0,026-0,141)	0,001	0,057	0,652	<0,001
Glutamine	42,8 (34,8-87,3)	109 (53,5-160)	111 (57,4-162)	0,001	<0,001	<0,001	0,429
AMP	2,0'/e-09 (1e-09-0,001)	0,006 (1,95e-09-0,019)	0,012 (0,001-0,022)	0,001	0,018	0,002	0,009
Cytidine	0,001 (0-0,003)	0 (0-4,21e-4)	0 (0-0,002)	0,001	<0,001	0,001	0,492
Cysteamine	0 (0-0)	0 (0-1.02e-11)	0 (0-0.001)	0.001	0,423	0,009	0,03
· · · · · ·	0,112	/	ALCONT A				
nicotinamide		0,132 (0,055-0,233)	0,169 (0,076-0,298)	0,002	0,595	0,11	0,001
	(0,037-0,261)		0.000				
Llanagurting	0,004	0,003	0,002	0.000	0.505	0.700	-0.001
nomocysune	(0-0.016)	(0-0.0144)	(0-0.007)	0,002	0,506	0,709	<0,001
Uracil	0.06 (0.037-0.067)	0.0382 (0.017-0.071)	0.0326 (0.012-0.06)	0.002	0.052	0.003	0.01
Ophthalmic acid	0 (0-0)	0 (0-0,002)	0 (0-0,002)	0,003	0,003	0,001	0,159
Dopamine	0,01 (0,004-0,0184)	0,0084 (1,75e-08-0,0158)	0,0113 (0,0044-0,0183)	0,004	0,522	0,639	0,001
	0		0,01	0.007		0.0	
Isocitric acid	(0.0.04)	0,0142 (0,003-0,032)	(0.0.028)	0,004	0,017	0,085	0,011
	0.01	0.008	(0-0,020)				
3.4-dihydroxyphenylalanine	0,01		0.011 (0.002-0.018)	0.004	0.997	0.286	0.001
	(0-0,016)	(0-0,016)	, (., 0,0.10)	.,		_,	-,-01
	36,9	46,6	53,6				
Tyrosine				0,006	0,021	0,002	0,072
	(20,9-47,4)	(27,8-82)	(51-81,5)				
Lysine	/ 3,4	141	100	0.006	0.006	0.002	0213
-y->-11-C	(56-125)	(64,3-219)	(69,7-226)	5,000	0,000	0,002	0,210
	29,1	20,8	19,6				
Histidine				0,006	0,008	0,003	0,136
Chalianaid	(23,1-34,1)	(12,7-33,2)	(11,6-31,9)	0.000	0.007	0.000	0.000
Cholic acid	0,002 (0,001-0,003)	0,002 (7,238-4-0,004)	0,001 (4,536-4-0,003)	0,008	0,967	0,299	0,002
Valine	/ 3,0	07,7	09,9	0.01	0.004	0.002	0.653
	(60,1-82)	(66,9-118)	(68,1-116)	5,01	0,004	0,002	0,000
		0,303	0,42				
α-Ketoglutaric acid	0,194 (5,71e-08-0,6)			0,01	0,386	0,169	0,004
		0,131-0,592)	(0,137-0,836)				

Note: "Significance" - p-value by the Kraskell-Wallis test. In the columns with the name of groups listed after comma - p-value of the posthoc test (Mann-Whitney test) for the designated groups. I - group of patients with mild disease course, II - group of patients with moderately severe disease course, III - group of patients with severe disease course. The table presents only those metabolites, the difference in the concentration of which was statistically significant (p0.01).

Table 4:	Metabolite concentrations in the blood of patients from different group	s divided by disease outcome [M	e (Q25-Q75)], numbers
less than	0.001 are presented by exponential entry [number e degree]		

Metabolite	V (Alive)	IV (Dead)	р
Threonine	7,88 (5,71-11,1)	6,9 (4,32-8,93)	<0,001
Cystathionine	0,15 (0,085-0,303)	0,251 (0,126-0,769)	<0,001
Malic acid	0,017 (0,008-0,026)	0,023 (0,013-0,045)	<0,001
Isocitric acid	0,014 (0,002-0,032)	0,005 (0-0,022)	<0,001
Pyruvic acid	0,026 (0-0,049)	0,016 (0-0,031)	<0,001
Lactic acid	12,3 (8,71-17,1)	15,6 (11,3-22,9)	<0,001
Uric acid	3,91 (2,7-5,66)	5,17 (3,46-7,85)	<0,001
Creatine	13 (7,94-21,9)	17,1 (9,61-40,3)	<0,001
Creatinine	38,9 (29,2-53,1)	49,3 (32,7-70,5)	<0,001
Pantothenic acid	0,089 (0,063-0,118)	0,106 (0,077-0,156)	<0,001
Dopamine	0,009 (0,001-0,016)	0,0135 (0,006-0,019)	<0,001
SAH	0,015 (0-0,028)	0,032 (0,018-0,055)	<0,001
kynurenine	1,63 (1,14-2,26)	2,4 (1,5-3,5)	<0,0001
phenylalanine	145 (83,9-218)	202 (143-258)	<0,0001
acetylcarnitine	68,1 (43-104)	110 (68,1-175)	<0,001
3,4-dihydroxyphenylalanine	0,008 (0-0,016)	0,013 (0,006-0,019)	<0,001
$\alpha - Ketoglutaricacid$	0,307 (0,129-0,598)	0,581 (0,149-1,09)	0,001
ТМР	0,006 (0-0,104)	0,025 (0,002-0,348)	0,001
Homocystine	0,003 (0-0,014)	0,001 (0-0,004)	0,001
citrulline	2,63 (0,89-4,29)	1,97 (0,78-3,04)	0,001
Hydroxylysine	0 (0-0,136)	0 (0-0,009)	0,001
Histamine	0,0162 (0-0,031)	0,025 (0-0,056)	0,001
cystine	1,88 (0,208-5,49)	2,83 (1,37-6,11)	0,001
AMP	0,006 (1,58e-09-0,012)	0,014 (0,001-0,024)	0,001
Fumaric acid	0(0-2,11e-08)	0 (0-0,009)	0,001
Lysteine	0,0749 (0,021-0,241)	0,0344 (0,0194-0,123)	0,001
Cytosine	0,013 (0,003-0,028)	0,021 (0,004-0,046)	0,001
Hypoxanthine	0,786 (0,387-1,29)	1,07 (0,504-1,72)	0,001
carnitine	26 (20,4-32,9)	28,6 (23,1-39,7)	0,001
Cholic acid	0,002 (6,61e-4-0,004)	9,92e-4(0,0002-0,003)	0,001
Thymidine	0 (0-0)	0 (0-0)	0,001
Isoleucine	43 (27,2-74,4)	56,4 (34,6-82,6)	0,003
Serotonin	0,0695 (0,03-0,181)	0,0389 (0,025-0,123)	0,003
$\gamma - glutamylcysteine$	0 (0-0,015)	0,01 (0-0,017)	0,003
Nicotinamide	0,136 (0,058-0,251)	0,184 (0,089-0,286)	0,003
Leucine	67,3 (41,7-110)	87,7 (55,5-123)	0,009
dimethylglycine	1,83 (1,25-2,72)	2,28 (1,34-4,1)	0,0099

Note: IV - group of patients with fatal outcome of the disease, V - group of patients successfully discharged after hospitalisation. "Significance" - p-value by the Mann-Whitney test. The table presents only those metabolites, the difference in the concentration of which is statistically significant (p0.01).